Table 4.
Incidence of ARIA by ApoE genotype.
| Anti-amyloid antibody | ApoE genotype | Incidence of ARIA-E (%) | Incidence of ARIA-H/siderosis (%) |
|---|---|---|---|
| Aducanumab (35) | ε4/ε4 | 64 | 41/33 |
| ε4/– | 36 | 17/14 | |
| –/– | 20 | 12/6 | |
| Lecanemab (3) | ε4 positive | 14.3 | 13.1 |
| ε4 negative | 8.0 | 4.6 | |
| Donanemab (5) | ε4/ε4 | 44.0 | |
| ε4/– | 30.0 | 19.8/17.6 (all genotypes) | |
| –/– | 11.1 | ||
| Gantenerumab (105 mg) (6) | ε4/ε4 | 10.7 | 32.0 |
| ε4/- | 5.4 | 19.8 | |
| –/– | 1.8 | 12.3 | |
| Gantenerumab (225 mg) (6) | ε4/ε4 | ? | ? |
| ε4/- | 15.0 | 19.4 | |
| –/– | 11.0 | 11.0 |
Incidence of ARIA-E and -H by ApoE genotype. ARIA-E and -H may have occurred concurrently in some individuals. [?] indicates data not available.